Poseida Therapeutics (PSTX) Has a New Rating from William Blair

By Austin Angelo

In a report released today, Raju Prasad from William Blair initiated coverage with a Buy rating on Poseida Therapeutics (PSTXResearch Report). The company’s shares closed last Thursday at $9.11, close to its 52-week low of $8.38.

According to TipRanks.com, Prasad is a 5-star analyst with an average return of 18.1% and a 60.0% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.

Currently, the analyst consensus on Poseida Therapeutics is a Strong Buy with an average price target of $25.00, which is a 183.4% upside from current levels. In a report issued on August 17, Piper Sandler also maintained a Buy rating on the stock with a $30.00 price target.

See today’s analyst top recommended stocks >>

Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PSTX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors.